This appraisal critically reviewed the manufacturer’s submission of the evidence for the clinical and cost effectiveness of eltrombopag for ITP as part of NICE’s single technology appraisal process.
From the results of the manufacturer's submission and additional analyses of the economic model conducted by the Evidence Review Group, it appeared that eltrombopag was a safe treatment for ITP (although long-term follow-up studies are awaited) and has short-term efficacy. However, there was no robust evidence on long-term efficacy or cost-effectiveness of eltrombopag, and there was a lack of robust direct evidence on the effectiveness and cost-effectiveness of eltrombopag compared with other relevant comparators
NICE did not recommend eltrombopag for the treatment of chronic ITP within its marketing authorisation for splenectomised or non-splenectomised patients.
Cynthia Fraser; firstname.lastname@example.org
Boyers D, Jia X, Crowther M, Jenkinson DJ, Fraser C, Mowatt G. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP): A Single Technology Appraisal. Health Technol Assess 2010;15(Suppl. 1):23-32.
Boyers D, Jia X, Mowatt G. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics 2012;30(6):483-95.